HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q4 2022 13F Holders as of 31 Dec 2022

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
129,468,465
Share change
-2,260,254
Total reported value
$7,364,542,615
Put/Call ratio
31%
Price per share
$56.90
Number of holders
414
Value change
-$117,989,602
Number of buys
187
Number of sells
194

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q4 2022

As of 31 Dec 2022, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 414 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 129,468,465 shares. The largest 10 holders included BlackRock Inc., VANGUARD GROUP INC, Artisan Partners Limited Partnership, Invesco Ltd., STATE STREET CORP, SNYDER CAPITAL MANAGEMENT L P, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, JPMORGAN CHASE & CO, MACQUARIE GROUP LTD, and GEODE CAPITAL MANAGEMENT, LLC. This page lists 414 institutional shareholders reporting positions in this security for the Q4 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.